523 related articles for article (PubMed ID: 21619430)
41. Interpreting the clinical utility of a pharmacogenomic marker based on observational association studies.
Sorich MJ; Coory M
Pharmacogenomics J; 2014 Feb; 14(1):1-5. PubMed ID: 24018622
[TBL] [Abstract][Full Text] [Related]
42. [From pharmacogenetics to pharmacogenomics: the start of a new era of personalized medicine in nephrology].
Zaza G; Granata S; Mangino M; Grandaliano G; Schena FP
G Ital Nefrol; 2010; 27(4):353-66. PubMed ID: 20672232
[TBL] [Abstract][Full Text] [Related]
43. Biomarkers and personalized therapy in chronic kidney diseases.
Schena FP
Expert Opin Investig Drugs; 2014 Aug; 23(8):1051-4. PubMed ID: 24857812
[TBL] [Abstract][Full Text] [Related]
44. miRNA pharmacogenomics: the new frontier for personalized medicine in cancer?
Dreussi E; Biason P; Toffoli G; Cecchin E
Pharmacogenomics; 2012 Nov; 13(14):1635-50. PubMed ID: 23148639
[TBL] [Abstract][Full Text] [Related]
45. Perception of the usefulness of drug/gene pairs and barriers for pharmacogenomics in Latin America.
Quinones LA; Lavanderos MA; Cayun JP; Garcia-Martin E; Agundez JA; Caceres DD; Roco AM; Morales JE; Herrera L; Encina G; Isaza CA; Redal MA; Larovere L; Soria NW; Eslava-Schmalbach J; Castaneda-Hernandez G; Lopez-Cortes A; Magno LA; Lopez M; Chiurillo MA; Rodeiro I; Castro de Guerra D; Teran E; Estevez-Carrizo F; Lares-Assef I
Curr Drug Metab; 2014 Feb; 15(2):202-8. PubMed ID: 24524664
[TBL] [Abstract][Full Text] [Related]
46. Pharmacogenomics: Prescribing Precisely.
Wake DT; Ilbawi N; Dunnenberger HM; Hulick PJ
Med Clin North Am; 2019 Nov; 103(6):977-990. PubMed ID: 31582008
[TBL] [Abstract][Full Text] [Related]
47. DruGeVar: an online resource triangulating drugs with genes and genomic biomarkers for clinical pharmacogenomics.
Dalabira E; Viennas E; Daki E; Komianou A; Bartsakoulia M; Poulas K; Katsila T; Tzimas G; Patrinos GP
Public Health Genomics; 2014; 17(5-6):265-71. PubMed ID: 25228099
[TBL] [Abstract][Full Text] [Related]
48. Pharmacogenomics: history, barriers, and regulatory solutions.
Blankstein S
Food Drug Law J; 2014; 69(2):273-314, ii. PubMed ID: 25163212
[TBL] [Abstract][Full Text] [Related]
49. Pharmacogenomics in the age of personalized medicine.
Dickmann LJ; Ware JA
Drug Discov Today Technol; 2016; 21-22():11-16. PubMed ID: 27978982
[TBL] [Abstract][Full Text] [Related]
50. How pharmacogenomics (PG) are changing practice: implications for prescribers, their patients, and the healthcare system (PG series part I).
Preskorn SH; Hatt CR
J Psychiatr Pract; 2013 Mar; 19(2):142-9. PubMed ID: 23507814
[TBL] [Abstract][Full Text] [Related]
51. Pharmacogenomic approaches to study the effects of antihypertensive drugs.
Kamide K; Kawano Y; Rakugi H
Hypertens Res; 2012 Aug; 35(8):796-9. PubMed ID: 22739423
[TBL] [Abstract][Full Text] [Related]
52. [Pharmacogenomic approaches for prevention of drug toxicity in cancer chemotherapy].
Hasegawa Y
Gan To Kagaku Ryoho; 2003 Mar; 30(3):325-33. PubMed ID: 12669388
[TBL] [Abstract][Full Text] [Related]
53. The phenotype standardization project: improving pharmacogenetic studies of serious adverse drug reactions.
Pirmohamed M; Aithal GP; Behr E; Daly A; Roden D
Clin Pharmacol Ther; 2011 Jun; 89(6):784-5. PubMed ID: 21593754
[TBL] [Abstract][Full Text] [Related]
54. Characteristics of pharmacogenomics/biomarker-guided clinical trials for regulatory approval of anti-cancer drugs in Japan.
Ishiguro A; Yagi S; Uyama Y
J Hum Genet; 2013 Jun; 58(6):313-6. PubMed ID: 23657427
[TBL] [Abstract][Full Text] [Related]
55. [Recommendations for performing pharmacogenetic tests in drug monographs in Canada, France and the United States].
Marquot G; Frison C; Lebel D; Bussières JF; Métras MÉ
Ann Pharm Fr; 2020 Sep; 78(5):447-457. PubMed ID: 32777298
[TBL] [Abstract][Full Text] [Related]
56. Pharmacogenomics: the promise of personalized medicine for CNS disorders.
de Leon J
Neuropsychopharmacology; 2009 Jan; 34(1):159-72. PubMed ID: 18800072
[TBL] [Abstract][Full Text] [Related]
57. Personalized medicine.
Jain KK
Curr Opin Mol Ther; 2002 Dec; 4(6):548-58. PubMed ID: 12596356
[TBL] [Abstract][Full Text] [Related]
58. Pharmacogenetics and pharmacogenomics of anticancer agents.
Huang RS; Ratain MJ
CA Cancer J Clin; 2009; 59(1):42-55. PubMed ID: 19147868
[TBL] [Abstract][Full Text] [Related]
59. Pharmacogenomics in anticoagulant drug development.
Iqbal O
Pharmacogenomics; 2002 Nov; 3(6):823-8. PubMed ID: 12437483
[TBL] [Abstract][Full Text] [Related]
60. The PharmGKB: integration, aggregation, and annotation of pharmacogenomic data and knowledge.
Hodge AE; Altman RB; Klein TE
Clin Pharmacol Ther; 2007 Jan; 81(1):21-4. PubMed ID: 17185992
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
